About ARCA
Our Science
Clinical Trials
Collaborations
Investors
Contact Us
About ARCA
Our Science
Clinical Trials
Collaborations
Investors
Contact Us
Investor Relations
Press Releases
[+view all]
02.20.2019
ARCA BIOPHARMA ANNOUNCES FDA AGREEMENT FOR A SINGLE PHASE 3 CLINICAL TRIAL TO SUPPORT APPROVAL FOR THE FIRST GENETICALLY-TARGETED CARDIOVASCULAR DRUG
12.20.2018
ARCA BIOPHARMA UPDATES SPECIAL PROTOCOL ASSESSMENT REQUEST TO FDA FOR GENCARO PHASE 3 ATRIAL FIBRILLATION CLINICAL TRIAL
11.14.2018
ARCA BIOPHARMA ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
About ARCA
Our Science
Clinical Trials
Collaborations
Investors
Contact Us
Investor Relations
Press Releases
[+view all]
02.20.2019
ARCA BIOPHARMA ANNOUNCES FDA AGREEMENT FOR A SINGLE PHASE 3 CLINICAL TRIAL TO SUPPORT APPROVAL FOR THE FIRST GENETICALLY-TARGETED CARDIOVASCULAR DRUG
12.20.2018
ARCA BIOPHARMA UPDATES SPECIAL PROTOCOL ASSESSMENT REQUEST TO FDA FOR GENCARO PHASE 3 ATRIAL FIBRILLATION CLINICAL TRIAL
11.14.2018
ARCA BIOPHARMA ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Presentations
[GO]
Annual Financial Reports
[GO]
SEC Filings
[GO]
Frequently Asked Questions
[GO]
Corporate Governance
Committee Charters
Audit Committee
Compensation Committee
Nominating & Governance Committee
Governance Documents
Board of Directors Corporate Governance Principles
ARCA biopharma, Inc. Code of Business Conduct and Ethics
ARCA biopharma, Inc. Complaint and Investigation Policy and Procedure
Contact the Board
Chairperson
Member
Audit Committee
Compensation Committee
Nominating & Governance Committee
Raymond L. Woosley, M.D., Ph.D.
Linda Grais, M.D.
Robert E. Conway
Dan Mitchell
Anders Hove, M.D.